Crestor and Application site erosion - a phase IV clinical study of FDA data

Summary:

Application site erosion is reported as a side effect among people who take Crestor (rosuvastatin calcium), especially for people who are female, 60+ old, also take Fentanyl-100, and have Back pain.

The phase IV clinical study analyzes which people have Application site erosion when taking Crestor. It is created by eHealthMe based on reports of 143,349 people who have side effects when taking Crestor from the FDA, and is updated regularly.

What is Crestor?

Crestor has active ingredients of rosuvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 149,763 Crestor users. Check the latest studies of Crestor.

What is Application site erosion?

Application site erosion is found to be associated with 105 drugs and 282 conditions by eHealthMe. Check the latest studies of Application site erosion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

143,349 people reported to have side effects when taking Crestor.
Among them, 11 people (0.01%) have Application site erosion.

Could Crestor cause Application site erosion?

Among these 11 people:

What is the gender of people who have Application site erosion when taking Crestor? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Application site erosion when taking Crestor? *

What are other drugs people take besides Crestor? *

What are other side effects people have besides Application site erosion? *

Application Site Erythema (redness of the skin at application site): 4 people, 36.36%
Application Site Pruritus (application site severe itching of the skin): 4 people, 36.36%
Application Site Rash: 3 people, 27.27%
Drug Ineffective: 2 people, 18.18%
Rashes (redness): 2 people, 18.18%
Itching: 2 people, 18.18%
Drug Effect Decreased: 1 person, 9.09%
Application Site Pain: 1 person, 9.09%
Application Site Swelling: 1 person, 9.09%
Arterial Occlusive Disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked): 1 person, 9.09%

What are the existing conditions these people have? *

Back Pain: 4 people, 36.36%
High Blood Pressure: 3 people, 27.27%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 2 people, 18.18%
Diabetes: 2 people, 18.18%
Thyroid Diseases: 1 person, 9.09%
Sleep Disorder: 1 person, 9.09%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 1 person, 9.09%
Pain: 1 person, 9.09%
Neuralgia (pain in one or more nerves): 1 person, 9.09%
Muscle Disorder (muscle disease): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Crestor and have Application site erosion?

- Check whether Application site erosion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Crestor:

Crestor (149,763 reports)

Browse all side effects of Crestor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site erosion:

Application site erosion (105 drugs)

Browse all the conditions that are associated with Application site erosion:

Application site erosion (282 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rosuvastatin calcium (the active ingredients of Crestor) and Crestor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.